J Neurol Surg B Skull Base 2021; 82(S 02): S65-S270
DOI: 10.1055/s-0041-1725492
Presentation Abstracts
Poster Abstracts

Meta-analysis of Adjuvant Radiotherapy for Intracranial Atypical and Malignant Meningiomas

Ansley Unterberger
1   David Geffen School of Medicine at UCLA, Los Angeles, California, United States
,
Thien Nguyen
2   Department of Neurosurgery at UCLA, Los Angeles, California, United States
,
Courtney Duong
2   Department of Neurosurgery at UCLA, Los Angeles, California, United States
,
Aditya Kondajji
1   David Geffen School of Medicine at UCLA, Los Angeles, California, United States
,
Daniel Kulinich
1   David Geffen School of Medicine at UCLA, Los Angeles, California, United States
,
Isaac Yang
2   Department of Neurosurgery at UCLA, Los Angeles, California, United States
› Author Affiliations
› Further Information
 
 

    Objective: In this study, we investigated the effect of adjuvant radiotherapy (ART) postsurgery on survival outcomes compared with surgery alone for high-grade meningiomas.

    Methods: PRISMA guidelines were a foundation for our literature review. We screened the PubMed database for studies reporting overall survival (OS), progression-free survival (PFS), and tumor recurrence for intracranial, primary AMs and MMs treated with surgery + ART or surgery alone. Fixed and random effect models compared tumor control rate for AM aforementioned groups.

    Results: Mean 5-year PFS was 76.9% for AM (surgery + ART) and 55.9% for AM (surgery alone) patients. Mean 5-year OS was 81.3 and 74% for AM (surgery + ART) and AM (surgery alone) groups, respectively. Overall, the mean 5-year PFS for aggregated high-grade meningiomas AM + MM (surgery + ART) was 67.6%. Fixed effect models revealed tumor control rate as 76% for AM (surgery + ART) and 69% for AM (surgery alone) groups.

    Conclusion: Our analysis suggests that (surgery + ART) may increase PFS, OS, and tumor control rates in high-grade meningiomas. However, further studies involving surgery + ART should be conducted to fully evaluate the ideal radiosurgical candidate, modality, and dosage.


    #

    No conflict of interest has been declared by the author(s).

    Publication History

    Article published online:
    12 February 2021

    © 2021. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany